1.53
price down icon1.29%   -0.02
after-market Handel nachbörslich: 1.53
loading
Schlusskurs vom Vortag:
$1.55
Offen:
$1.57
24-Stunden-Volumen:
213.28K
Relative Volume:
0.44
Marktkapitalisierung:
$47.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.3825
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
+5.52%
1M Leistung:
+9.29%
6M Leistung:
-71.88%
1J Leistung:
-81.32%
1-Tages-Spanne:
Value
$1.51
$1.58
1-Wochen-Bereich:
Value
$1.40
$1.68
52-Wochen-Spanne:
Value
$0.87
$9.2899

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Firmenname
Outlook Therapeutics Inc
Name
Telefon
(609) 619-3990
Name
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Name
Mitarbeiter
23
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-14
Name
Neueste SEC-Einreichungen
Name
OTLK's Discussions on Twitter

Vergleichen Sie OTLK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
OTLK
Outlook Therapeutics Inc
1.53 47.95M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-02 Herabstufung Chardan Capital Markets Buy → Neutral
2024-03-27 Hochstufung BTIG Research Neutral → Buy
2024-02-15 Hochstufung Chardan Capital Markets Neutral → Buy
2024-01-25 Hochstufung Guggenheim Neutral → Buy
2023-12-27 Hochstufung CapitalOne Equal Weight → Overweight
2023-08-31 Herabstufung Chardan Capital Markets Buy → Neutral
2023-08-31 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-30 Herabstufung BTIG Research Buy → Neutral
2023-08-30 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-08-30 Herabstufung CapitalOne Overweight → Equal Weight
2023-08-30 Herabstufung Guggenheim Buy → Neutral
2023-07-13 Eingeleitet CapitalOne Overweight
2023-04-03 Eingeleitet Guggenheim Buy
2023-02-06 Eingeleitet Cantor Fitzgerald Overweight
2022-10-31 Eingeleitet BTIG Research Buy
2022-09-13 Eingeleitet Chardan Capital Markets Buy
2019-09-11 Eingeleitet Ladenburg Thalmann Buy
2019-05-16 Eingeleitet Oppenheimer Outperform
2019-04-22 Eingeleitet Ascendiant Capital Markets Buy
Alle ansehen

Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten

pulisher
Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025
pulisher
Apr 19, 2025

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN

Apr 19, 2025
pulisher
Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail

Apr 17, 2025
pulisher
Apr 12, 2025

25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Outlook Therapeutics Approves Retention Incentive for CFO - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com

Apr 10, 2025
pulisher
Apr 10, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 09, 2025

FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire

Apr 08, 2025
pulisher
Apr 08, 2025

Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025
pulisher
Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 01, 2025

Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire

Mar 01, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat

Feb 23, 2025
pulisher
Feb 21, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World

Feb 20, 2025

Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):